Viridian Therapeutics, Inc.\DE: A 2025 Annual Report Summary

This summary reviews Viridian Therapeutics, Inc.'s performance for the fiscal year ending December 31, 2025. Viridian Therapeutics trades on The Nasdaq Stock Market LLC under the ticker symbol VRDN. As a "well-known seasoned issuer," Viridian benefits from streamlined access to capital markets, allowing for quicker and more flexible fundraising when needed.

Business Overview

Viridian Therapeutics is a clinical-stage biotechnology company that develops novel therapies for serious diseases. The company primarily focuses on advancing its pipeline of drug candidates, particularly those targeting autoimmune and inflammatory conditions.

Financial Performance

For fiscal year 2025, Viridian reported a net loss of $185 million, an increase from a $130 million net loss in 2024. This expanded loss primarily reflects a significant acceleration in research and development (R&D) activities.

• Revenue: The company generated $15 million in collaboration revenue in 2025, up from $5 million in the prior year. This revenue largely stemmed from a strategic partnership initiated in late 2024, indicating early success in leveraging its scientific expertise.
• Research & Development (R&D) Expenses: R&D expenses surged to $160 million in 2025 from $105 million in 2024. This substantial increase reflects accelerated spending on lead clinical programs, VRDN-123 and VRDN-456, as well as preclinical development for new candidates.
• General & Administrative (G&A) Expenses: G&A expenses remained relatively stable at $40 million in 2025, a slight increase from $35 million in 2024, supporting corporate operations and infrastructure.

Risk Factors

Investors should understand several key risks facing Viridian's business:

1. Clinical Trial Success: Drug candidates (e.g., VRDN-123, VRDN-456) may fail to demonstrate efficacy or safety in clinical trials, or may not meet regulatory requirements.
2. Regulatory Approval: Even with positive trial data, regulatory agencies like the FDA may not grant approval.
3. Competition: The market for autoimmune and inflammatory diseases is highly competitive. Competitors may develop more effective or cheaper treatments.
4. Intellectual Property: Protecting intellectual property is crucial. Challenges to patents or the emergence of biosimilars could impact future revenues.
5. Future Funding: Viridian will likely need to raise additional capital in the future, which could dilute existing shareholders or involve unfavorable terms.

Management Discussion and Analysis (MD&A) Highlights

Management discussed the company's operational progress and strategic direction during 2025. The increased net loss and R&D expenses reflect a deliberate acceleration of clinical development activities for lead programs VRDN-123 and VRDN-456.

Operational Highlights:

• Clinical Progress: The company successfully completed enrollment for its Phase 2b clinical trial for VRDN-123, a potential treatment for Thyroid Eye Disease (TED), in Q3 2025. Viridian also initiated a Phase 1 clinical trial for VRDN-456, targeting a rare inflammatory disorder, in Q1 2025.
• Strategic Partnership: A collaboration agreement signed in late 2024 provided non-dilutive funding and validated the company's platform technology, contributing to early revenue generation.
• Intellectual Property Expansion: Viridian strengthened its patent portfolio with the issuance of three new patents covering novel compounds and methods of use for its pipeline candidates.

Key Challenges and Strategic Responses:

• Increased Cash Burn: Accelerated R&D spending led to a higher cash burn rate, necessitating careful financial management.
• Competitive Landscape: Competition is intensifying in Viridian's target therapeutic areas. The company aims to differentiate its candidates through potential for convenient dosing, favorable safety profiles, and novel mechanisms of action.
• Clinical Trial Risks: Management continuously monitors and mitigates risks associated with clinical trial outcomes, delays, or unfavorable results, which could significantly impact the company's valuation.

Strategic Focus and Leadership:

• Viridian's executive leadership team remained stable in 2025, ensuring consistent strategic direction.
• The company's strategic focus remains on:
  1. Accelerating Lead Programs: Prioritizing the rapid and efficient advancement of VRDN-123 through late-stage clinical development.
  2. Pipeline Expansion: Continuing to invest in preclinical research to identify and develop new drug candidates for high-need indications.
  3. Strategic Partnerships: Exploring additional collaborations to leverage technology, share development costs, and potentially expand into new markets.

Market Trends and Regulatory Environment:

• An increased focus on rare diseases continues to influence the biotechnology sector, aligning with Viridian's pipeline.
• Management monitors ongoing debates around drug pricing and healthcare costs, which could impact future commercialization strategies and profitability.
• The company actively tracks evolving regulatory landscapes and FDA guidance, particularly for novel therapies, to adapt its development strategies.

Financial Health

As of December 31, 2025, Viridian reported $250 million in cash, cash equivalents, and marketable securities. This compares to $380 million at the end of 2024, reflecting significant investment in R&D activities throughout the year.

• Debt: The company maintains a healthy balance sheet with no significant long-term debt.
• Liquidity: Based on current operational plans and projected expenditures, Viridian estimates its existing cash resources are sufficient to fund operations into late 2027. However, future capital raises may be necessary to complete later-stage clinical trials or support potential commercialization efforts.

Future Outlook

Looking ahead to 2026, Viridian's key milestones include:

• Q2 2026: Anticipated top-line data readout from the Phase 2b trial of VRDN-123 for TED.
• H2 2026: Potential initiation of a Phase 3 clinical trial for VRDN-123, contingent on positive Phase 2b results and regulatory discussions.
• Year-end 2026: Expected initial safety data from the Phase 1 trial of VRDN-456.
• Ongoing: Continued preclinical development and potential Investigational New Drug (IND) filings for new pipeline candidates.

The company is optimistic about its ability to achieve these milestones, which are critical for demonstrating the value of its pipeline and attracting further investment.

Competitive Position

Viridian aims to differentiate its lead candidate, VRDN-123, in the Thyroid Eye Disease (TED) market by offering a potentially more convenient dosing regimen and a favorable safety profile compared to existing therapies. In the rare inflammatory disorder space, VRDN-456 is designed to address an unmet medical need with a novel mechanism of action, positioning it as a potential first-in-class treatment. The company's focus on targeted therapies with strong scientific rationale underpins its competitive strategy.